Ablation of Hepatocyte Derived‐ FGL1 Does Not Aggravate Metabolic Dysfunction‐Associated Steatotic Liver Disease
The FASEB Journal · 2025
DOI: 10.1096/fj.202501997r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Jean Personnaz und 8 weiteren Autor:innen. Beteiligte Einrichtung: IRSD, INSERM, INRAE, ENVT, Univ Toulouse III-Paul Sabatier (UPS), Université de Toulouse, Toulouse, France. Hauptthemen laut MEDLINE: Hepatocytes, Fatty Liver, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EC | European Research Council (ERC), Agence Nationale de la Recherche (ANR), Fondation ARC pour la Recherche sur le Cancer (ARC).
Abstract (Originalsprache)
Metabolic dysfunction‐associated steatotic liver disease (MASLD) begins with simple steatosis, which can progress to hepatocellular carcinoma (HCC). The pathogenesis of MASLD alters the secretion of hepatokines such as fibrinogen‐like 1 (FGL1), a candidate mediator of liver steatosis and hyperglycemia. To investigate the contribution of FGL1 to liver diseases, we compared wild‐type mice to mice with hepatocyte‐specific deletion of Fgl1 subjected to a steatosis or HCC experimental protocol. We found that mice deficient for Fgl1 in hepatocytes showed higher levels of plasma glucose, pronounced metabolic alterations, and liver injury when fed a western diet compared to their wild‐type counterparts. However, both genotypes exhibited similar lipid deposition in the liver. Similarly, wild type and Fgl1 ‐deficient mice displayed comparable liver alterations during HCC progression. We observed that FGL1 expression was repressed during MASLD progression in mice and humans concomitantly with the severity of liver injury. Altogether, these findings suggest that FGL1 is not a major contributor to the pathogenesis of MASLD and HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRSD, INSERM, INRAE, ENVT, Univ Toulouse III-Paul Sabatier (UPS), Université de Toulouse, Toulouse, France.
- Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP-PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
ORCID-Profile: Léon Kautz
Förderung
- EC | European Research Council (ERC)
- Agence Nationale de la Recherche (ANR)
- Fondation ARC pour la Recherche sur le Cancer (ARC)
- Fondation pour la Recherche Médicale (FRM)
- European Research Council
Zitieren
APA
Personnaz, J., Cannizzo, L., Martin, C. M. P., Desquesnes, A., Sotin, M., DaSilva, J., Perrier, P., Guillou, H., & Kautz, L. (2025). Ablation of Hepatocyte Derived‐ FGL1 Does Not Aggravate Metabolic Dysfunction‐Associated Steatotic Liver Disease. The FASEB Journal. https://doi.org/10.1096/fj.202501997r
Vancouver
Personnaz J, Cannizzo L, Martin CMP, Desquesnes A, Sotin M, DaSilva J, et al. Ablation of Hepatocyte Derived‐ FGL1 Does Not Aggravate Metabolic Dysfunction‐Associated Steatotic Liver Disease. The FASEB Journal. 2025. doi:10.1096/fj.202501997r
BibTeX
@article{Personnaz2025,
author = {Personnaz, Jean and Cannizzo, Lisa and Martin, Céline Marie Pauline and Desquesnes, Aurore and Sotin, Manon and DaSilva, Joanna and Perrier, Prunelle and Guillou, Hervé and Kautz, Léon},
title = {Ablation of Hepatocyte Derived‐ FGL1 Does Not Aggravate Metabolic Dysfunction‐Associated Steatotic Liver Disease},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202501997r}
}
EUVIMED